Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Treatment of Chronic Lymphocytic Leukemia


For chronic lymphocytic leukemia, there is no clear evidence that disease-directed treatment has a life-prolonging effect. The treatment can, however contribute to extending remission and symptom-free periods. This means that treatment is initiated when the disease causes symptoms.  


The most common indications for anti-leukemic treatment of chronic lymphatic leukemia:

  • bone marrow failure equivalent to Binet's stage C
  • general symptoms such as weight loss and night sweats
  • large symptom-causing tumor
  • troublesome lymph node tumor
  • rapidly progressive lymphocytosis (lymphocyte doubling time < 6 months)
  • autoimmune hemolytic anemia and/or immune-mediated thrombocytopenia, which does not respond to high doses of steroids or is recurring after reduction of treatment intensity.


  • For the patient to be symptom-free as long as possible.
  • To maintain good quality of life for the patient.








Norsk selskap for hematologi. Handlingsprogram for kronisk lymfatisk leukemi [Online] 2005 [hentet 15. april 2007]; tilgjengelig fra: URL:

Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website. Oslo University Hospital© 2018